Skip to main content
Displaying 57 of 2876 articles.

Rockefeller scientists launch a broad range of studies into novel coronavirus

Rockefeller University experts in infectious disease, immunology, biochemistry, structural biology, and genetics have begun over a dozen projects in recent weeks aimed at better understanding the biology of the SARS-CoV-2 virus, which is responsible for the current global COVID-19 pandemic...

Rockefeller begins testing of new COVID-19 antibody drug in people

With green light from the FDA, Rockefeller scientists started human trials this week for a new monoclonal antibody drug as a potential treatment for COVID-19. Monoclonal antibodies are mass-produced replicas of natural antibodies made by the immune system to fight viruses. Designed to prev...

Study of “breakthrough” cases suggests COVID testing may be here to stay

In rare cases, people who have been fully vaccinated against COVID and are immune to the virus can nevertheless develop the disease. New findings from The Rockefeller University now suggest that these so-called breakthrough cases may be driven by rapid evolution of the virus, and that ongo...

Rockefeller scientists investigate life-threatening inflammation affecting children with COVID-19

...As part of an international study of genetic causes behind severe COVID-19 in young people, Casanova and collaborators have been enrolling these unusual cases since early March, when they were first reported by European doctors. Collaborating with the New York Genome Center and the stat...

What bats can teach us about COVID-19

...But at the outset of the COVID-19 pandemic, he diverted his expertise and applied the same methods to instead to see if they could crack the mystery of bats’ exceptional immunity to coronavirus. His group began by sequencing the genome of the horseshoe bat, thought to be the initial hos...

The immune system mounts a lasting defense after recovery from COVID-19

As the number of people who have fought off SARS-CoV-2 climbs ever higher, a critical question has grown in importance: How long will their immunity to the novel coronavirus last? A new Rockefeller study offers an encouraging answer, suggesting that those who recover from COVID-19 are prot...

Rockefeller grants commercial license for the development of monoclonal antibodies for treatment of COVID-19

With promising results from preclinical studies and with human trials now underway, Rockefeller has taken the next step with its novel COVID-19 treatment. The university has entered a licensing agreement with a global pharmaceutical company to advance development of a drug based on two mon...

Scientists trace severe COVID-19 to faulty genes and autoimmune condition

More than 10 percent of people who develop severe COVID-19 have misguided antibodies that attack not the virus, but the immune system itself, new research shows. Another 3.5 percent, at least, carry a specific kind of genetic mutation. In both groups, the upshot is basically the same: The ...

Synthetic “micro lungs” could take COVID-19 research to the next level

...Research aimed to understand how COVID-19 wreaks havoc in the lungs, for example, has often been done with miscellaneous lung cancer cells that show crucial differences with the cells targeted by the virus. “There has been too much shifting ground for precise work,” says Ali H. Brivanlo...

The gene hunt to explain why some young, healthy people die from COVID-19

...Casanova, along with Helen Su at the National Institute of Allergy and Infectious Diseases are leading an international project, the COVID Human Genetic Effort, to comb through the genomes of many COVID-19 outliers in search of any rare gene variant that they may share, and that ...